Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 10/08/25
Royalty Pharma plc (RPRX) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum TranscriptSeeking Alpha • 09/23/25
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value CreationGlobeNewsWire • 09/11/25
Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty MarketGlobeNewsWire • 09/10/25
Royalty Pharma Plc (RPRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/09/25
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare ConferenceGlobeNewsWire • 09/04/25
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 MillionGlobeNewsWire • 09/02/25
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 MillionGlobeNewsWire • 09/02/25
Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 millionReuters • 08/25/25
Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 MillionGlobeNewsWire • 08/25/25
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 MillionBusiness Wire • 08/25/25
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 EarningsZacks Investment Research • 08/06/25
Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPSZacks Investment Research • 08/05/25
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of DirectorsGlobeNewsWire • 07/17/25